• Publications
  • Influence
Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers.
BACKGROUND GPI 15715 (AQUAVAN injection) is a new water-soluble prodrug which is hydrolyzed to release propofol. The objectives of this first study in humans were to investigate the safety,Expand
  • 79
  • 2
  • PDF
An Investigation of the Effectiveness of Exercise and Manual Therapy in Treating Symptoms of TMJ Osteoarthritis
ABSTRACT The background and purpose of this investigation was to evaluate the use of a treatment protocol which included active and passive jaw movements, manual therapy techniques, correction ofExpand
  • 39
  • 2
Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor.
A series of 2-(thioalkyl)pentanedioic acids were synthesized and evaluated as inhibitors of glutamate carboxypeptidase II (GCP II, EC 3.4.17.21). The inhibitory potency of these thiol-based compoundsExpand
  • 64
  • 1
AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics.
BACKGROUND AQUAVAN Injection (AQ) (GPI 15715; Guilford Pharmaceutical Inc., Baltimore, MD) is a water-soluble prodrug of propofol (PropofolGPI). This study aimed to explore the pharmacokinetics ofExpand
  • 64
  • 1
Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats
Background and objective: We studied the pharmacokinetics and pharmacodynamics of GPI 15715 (Aquavan® injection), a new water-soluble prodrug metabolized to propofol by hydrolysis. Methods: NineExpand
  • 52
A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.
TPS3152Background: Type I insulin-like growth factor receptor (IGF-1R) is a transmembrane protein which is overexpressed in solid tumors including non–small cell lung, prostate, and breast cancers....
  • 3
  • PDF